Forum Agenda
-
Keynote Forum: The Global Journey of China’s Innovation Drugs
-
-
Future-Driven Intelligent R&D–AI for Life Sciences and Drug Discovery
-
The Era of Superintelligent Agents for Chinese Innovative Drugs
-
Panel Discussion: AI-Empowered Four-in-One Translation Platform
-
AI-Driven Innovation Practices in Pharmaceutical Enterprises
-
AI·Intelligent Transformation: From Data Foundation to Scenario Value
-
-
Medicine-Engineering Integration and Innovative Medical Devices
-
Cross-Border Cooperation and China’s New Drug Global Expansion
-
Global Development of Pharma Enterprises and Emerging Market Cooperation
-
China-Japan Cooperation Session: Leveraging Japan’s Market to Boost Overseas Expansion Strategies
-
Legal Safeguard and Value Empowerment for Globalization of Chinese Pharma Enterprises
-
Clinical Development of Next-Generation Innovative Oncology Drugs
-
Global BD Cooperation Session for Innovative Drugs – Track 1, 2 & 3
-
Collaboration Between North American and Chinese Innovative Drug Industries
-
Biosimilars Commercialization & Global Launch Session(China Focus)
-
Protheragen Session: Global Biomedical Cross-Border Transactions
-
Clinical Development of Next-Generation Innovative Oncology Drugs
-
U.S. Biotech Tensions and the Future Road for Chinese Pharmaceutical Companies Going Global Session
-
July 22, 13:30-17:30
Global Innovation of Antibodies and ADCs session
Stay tuned
13:30-13:45 Global Innovation Strategy of DualityBio
John Zhu: Chairman, DualityBio
13:45-14:00 Global Collaboration Opportunities and Clinical Progress of Alphamab Oncology's Product Pipeline
Ting Xu: Chairman & President, Alphamab Oncology
14:00-14:15 Restructuring the Value Chain of Antibody and ADCs from Local to Global
Cuiling Song: Senior Application & Product Director, Bailinke
14:15-14:30 Differentiated Clinical Strategies for ADC Global Expansion and Development
Tongtong Xue: CEO, MediLink Therapeutics
14:30-14:45 Global Collaboration Opportunities and Clinical Progress of ImmuneOnco's Product Pipeline
Wenzhi Tian: Founder & Chairman, ImmuneOnco Biopharmaceuticals
14:45-15:00 Beyond Supply: Innovative Toolchains to Systematically Accelerate ADC Development
Xiaojing An: Dean of Sino Biological Innovation Research Institute
15:00-15:15 Innovation Strategy of Lepu Biopharma
Ziye Sui: CEO, Lepu Biopharma
15:15-15:30 Innovation Strategy of 3S Bio
Yanli Liu: General Manager, 3S Bio
15:30-15:45 Antibody Innovation Strategy of Affinity Biopharma
Chen Liu: Founder, President & Co-CMO, Affinity Biopharma
15:45-16:00 Engineering Strategies to Maximize the Efficacy of Antibody-Drug Conjugates
Changshou Gao: CTO, Shanghai Allist Pharmaceuticals
16:00-16:15 Innovation Strategy of Mabwell
Ke Hu: Senior Vice President, Mabwell
16:15-16:30 Precision Modeling Empowers a New Paradigm in Drug R&D: Application Value of Fully Humanized Mouse Models in Preclinical Research
Yuan Dong: R&D Director, China, Genovo Biotech
16:30-16:45 A Global Perspective on ADC Development
Junli Zhang: Senior Vice President, ADC BU Head and MFG Sites Head, Zencore Biologics
16:45-17:00 AI-Driven Precision and Scalability Empowering Next-Generation Dual-Payload ADCs
Yi Yang: CSO, Biocytogen
17:00-17:15 Global Development Strategy of Transcenta Holding's Antibody Drugs
Xueming Qian: CEO, Transcenta Holding
17:15-17:30 Digital-Intelligence Integration: Reconstructing Cell Culture Media and Bioprocess Development
Max Wang: CEO, MediumBank